Company: CNTB
Filing Date: 2025-09-16
Form Type: 8-K
Source: 0001835268-25-000056
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-16
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

Barry D. Quart, Pharm. D., Chief Executive Officer and Director of Connect Biopharma Holdings Limited (the “ Company”), purchased a total of 224,034 shares of the Company in a series of transactions occurring between September 2024 and September 2025.

David Szekeres, President of the Company, purchased a total of 215,739 shares of the Company in a series of transactions occurring between November 2024 and September 2025.

All purchases described in this Item 7.01 were made in compliance with the Company’s Insider Trading Compliance Policy, as in effect at the applicable times.

The information in Item 7.01 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no obligation to publicly update any information furnished in this Item 7.01, whether because of future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                 CONNECT BIOPHARMA HOLDINGS LIMITED  
  Date:      September 16, 2025      By:         /s/ David Szekeres                  
                                     Name:       David Szekeres                      
                                     Title:      President